Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
+$0.02 today
- Market cap
- $241.11M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
Volume 10.55M
Average 10.19M
ALLO Common Stock Issued
Cash raised by issuing new shares.
Allogene Therapeutics, Inc.NASDAQ: ALLO
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued growth accelerates
Q1 FY2026 common stock issued of $21.12M rose 111.2% year over year, ahead of the -72.5% change in trailing-twelve-month common stock issued. Sequentially, it rose 168.8% from the prior quarter. Over 3 fiscal years it compounded at +99.0% a year.
Context
- Common stock issued increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +111.2% holds above the trailing-twelve-month pace of -72.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 23.25M USD
- Year-over-year change
- -79.7%
- 4-year CAGR
- +18.1%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.25M | -79.7% |
| FY2024 | 2024-12-31 | 114.4M | +25.6% |
| FY2023 | 2023-12-31 | 91.11M | +2988.5% |
| FY2022 | 2022-12-31 | 2.95M | -75.3% |
| FY2021 | 2021-12-31 | 11.96M | — |
Common Stock Issued vs competitors
How ALLO compares with its peers on the latest reported figures
- ALLO's LTM Mar 2026 common stock issued of $33.73M is the 3rd largest of the 9 companies compared; the peer median is $13.4M.
- Its year-over-year change of -72.5% is the 7th highest of 9, against a peer median of +86.7%.
- Over three fiscal years its annual growth of +99.0% compares with a peer median of -9.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $126.68M | +124.3% | -81.5% | — | |
| LTM Mar 2026 | $85.22M | +309.7% | +8.6% | 189.1% | |
| LTM Mar 2026 | $33.73M | -72.5% | +99.0% | — | |
| LTM Dec 2025 | $26.88M | +343.6% | -22.9% | 101.2% | |
| LTM Mar 2026 | $19.29M | -45.8% | -9.3% | 83.4% | |
| LTM Mar 2026 | $7.51M | +73.4% | +31.2% | 67.0% | |
| LTM Mar 2026 | $74.25K | -99.9% | — | 0.1% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding ALLO) | $13.4M | +86.7% | -9.3% | 67.0% | |
Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (257.01M) | (332.63M) | (327.27M) | (257.59M) | (190.89M) |
| Depreciation & Amortization | 10.45M | 14.3M | 14.2M | 13.64M | 12.36M |
| Deferred Income Tax | 10.4M | 8.08M | 0 | 443K | 0 |
| Stock-Based Compensation | 80.82M | 83.6M | 65.95M | 51.74M | 37.64M |
| Change in Working Capital | (32.09M) | 3.71M | (15.31M) | (24.8M) | (10.88M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (767K) | 4.87M | (7.5M) | (503K) | (1.23M) |
| Other Working Capital | (31.32M) | (1.16M) | (7.8M) | (24.3M) | (9.65M) |
| Other Non-Cash Items | 2.61M | 2.43M | 24.69M | 16.26M | 2.52M |
| Operating Cash Flow | (184.81M) | (220.52M) | (237.73M) | (200.3M) | (149.25M) |
| Capital Expenditures | (21.45M) | (5.19M) | (1.52M) | (694K) | (386K) |
| Acquisitions (Net) | (17.71M) | (111.35M) | 0 | 0 | 0 |
| Purchases of Investments | (525.58M) | (248.11M) | (438.63M) | (361.48M) | (138.26M) |
| Sales of Investments | 728.39M | 359.46M | 603.43M | 437.86M | 234.2M |
| Other Investing Activities | 0 | 111.35M | 0 | 0 | 0 |
| Investing Cash Flow | 163.66M | 106.16M | 163.29M | 75.69M | 95.56M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 11.96M | 2.95M | 91.11M | 114.4M | 23.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 4.58M | 2.28M | 6.91M |
| Financing Cash Flow | 11.96M | 2.95M | 95.7M | 116.68M | 30.16M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.19M) | (111.41M) | 21.25M | (7.94M) | (23.53M) |
| Free Cash Flow | (206.26M) | (225.71M) | (239.25M) | (200.99M) | (149.63M) |
Allogene Therapeutics, Inc.
NASDAQ:ALLO
Intrinsic Alpha fair value
Locked
Current Price
$0.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.